The bipyridyl herbicide paraquat induces proteasome dysfunction in human neuroblastoma SH-SY5Y cells

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 70, Issue 21, 2007, Pages 1849-1857

  Yang, Wonsuk ^a   Tiffany Castiglioni, Evelyn ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; BIPYRIDINE DERIVATIVE; PARAQUAT; UBIQUITIN CONJUGATING ENZYME;

ARTICLE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; MITOCHONDRION; NEUROBLASTOMA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION;

CELL SURVIVAL; HERBICIDES; HUMANS; L-LACTATE DEHYDROGENASE; MITOCHONDRIA; NEUROBLASTOMA; PARAQUAT; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR CELLS, CULTURED;

MUS;

EID: 35348884153     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390701459262     Document Type: Article

References (75)

1. Abou-Sleiman, P. M., Muqit, M. K., and Wood, N. W. 2006. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7:207-219.
2. Andersen, J. K. 2003. Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease. Neurotoxicol. Res. 5:307-314.
3. Barnham, K. J., Masters, C. L., and Bush, A. I. 2004. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3:205-214.
4. Barrientos, A., Kenyon, L., Moraes, C. T. 1998. Human xenomitochondrial cybrids. Cellular models of mitochondrial complex I deficiency. J. Biol. Chem. 273:14210-14217.
5. Ben-Shachar, D., Zuk, R., Gazawi, H., and Ljubuncic, P. 2004. Dopamine toxicity involves mitochondrial complex I inhibition: Implications to dopaminerelated neuropsychiatric disorders. Biochem. Pharmacol. 67:1965-1974.
6. Biasini, E., Fioriti, L., Ceglia, I., Invernizzi, R., Bertoli, A., Chiesa, R., and Forloni, G. 2004. Proteasome inhibition and aggregation in Parkinson's disease: A comparative study in untransfected and transfected cells. J. Neurochem. 88:545-553.
7. Bismuth, C., Garnier, R., Baud, F. J., Muszynski, J., and Keyes, C. 1990. Paraquat poisoning. An overview of the current status. Drug Safety 5:243-251.
8. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
9. Brooks, A. I., Chadwick, H. A., Gelbard, D. A., Cory-Slechta, D. A., and Federoff, H. J. 1999. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 823:1-10.
10. Carrard, G., Bulteau, A. L., Petropoulos, I., and Friguet, B. 2002. Impairment of proteasome structure and function in aging. Int. J. Biochem. Cell Biol. 34:1461-1474.
11. Chung, K. K., Dawson, V. L., and Dawson, T. M. 2001. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. Suppl. 24:S7-S14.
12. Ciechanover, A., and Brundin, P. 2003. The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron 40:427-446.
13. Cremlyn, J. R. 1991. Agrochemicals: Preparation and mode of action. Chichester, England: Wiley.
14. DeMartino, G. N., and Slaughter, C. A. 1999. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274:22123-22126.
15. Denizot, F., and Lang, R., 1986. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89:271-277.
16. Dev, K. K., Hofele, K., Barbieri, S., Buchman, V. L., and van der Putten, H. 2003. Part II: Alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45:14-44.
17. Ding, Q., and Keller, J. N. 2001. Proteasome inhibition in oxidative stress neurotoxicity: Implications for heat shock proteins. J. Neurochem. 77:1010-1017.
18. Di Monte, D. A. 2003. The environment and Parkinson's disease: Is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2:531-538.
19. Elkon, H., Melamed, E., and Offen, D. 2001. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: Implications for the pathogenesis of Parkinson's disease. Cell Mol. Neurobiol. 21:771-781.
20. Elkon, H., Melamed, E., and Offen, D. 2004. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: Implications for the pathogenesis of Parkinson's disease. J. Mol. Neurosci. 24:387-400.
21. Glickman, M. H., and Ciechanover, A. 2002. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction, Physiol. Rev. 82:373-428.
22. Goldberg, A. L. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426:895-899.
23. Gómez-Santos, C., Ambrosio, S., Ventura F., Ferrer, I., and Reiriz, J. 2002. TGF-beta1 increases tyrosine hydroxylase expression by a mechanism blocked by BMP-2 in human neuroblastoma SH-SY5Y cells. Brain Res. 958:152-160.
24. Gómez-Santos, C., Ferrer, I., Santidrian, A. F., Barrachina, M., Gil, J., and Ambrosio, S. 2003. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J. Neurosci. Res. 73:341-350.
25. Grant, H., Lantos, P. L., and Parkinson, C. 1980. Cerebral damage in paraquat poisoning. Histopathology 4:185-195.
26. Hashimoto, M., Rockenstein, E., Crews, L., and Masliah, E. 2003. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromol. Med. 4:21-36.
27. Hertzman, C., Wiens, M., Bowering, D., Snow, B., and Calne, D. 1990. Parkinson's disease: A case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 17:349-355.
28. Hoglinger, G. U., Carrard, G., Michel, P. P., Medja, F., Lombes, A., Ruberg, M., Friguet, B., and Hirsch, E. C. 2003. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86:1297-1307.
29. Hughes, J. T. 1988. Brain damage due to paraquat poisoning: A fatal case with neuropathological examination of the brain. Neurotoxicology 9:243-248.
30. Hyun, D. H., Gray, D. A., Halliwell, B., and Jenner, P. 2004. Interference with ubiquitination causes oxidative damage and increased protein nitration: Implications for neurodegenerative diseases. J. Neurochem. 90:422-430.
31. Keller, J. N., Huang, F. F., Dimayuga, E. R., and Maragos, W. F. 2000. Dopamine induces proteasome inhibition in neural PC12 cell line. Free Radical Biol. Med. 29:1037-1042.
32. Klegeris, A., and McGeer, P. L. 2000. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp. Neurol. 166:458-464.
33. 2+ and neurodegenerative disease. Eur. J. Pharmacol. 447:177-188.
34. Lai, C. T., and Yu P. H. 1997. Dopamine- and L-β-3,4- dihydrophenylalanine hydrochloride (L-dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Ycells. Biochem. Pharmacol. 53:363-372.
35. Langston, J. W., Ballard, P. A., Terud, J. W., and Irwin, I. 1983. Chronic parkinsonism in humans due to a product of merperidine analog synthesis. Science 219:979-980.
36. Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., and Karluk, D., 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropryidine exposure. Ann. Neurol. 46:598-605.
37. Lee, H. S., Park, C. W., and Kim, Y. S. 2000. MPP+ increases the vulnerability to oxidative stress rather than directly mediating oxidative damage in human neuroblastoma cells. Exp. Neurol. 165:164-171.
38. Legros, H., Dingeval, M. G., Janin, F., Costentin, J., and Bonnet, J. J. 2004. Toxicity of treatment asociating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: Relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology 25:365-375.
39. Liou, H. H., Chen, R. C., Tsai, Y. F., Chen, W. P., Chang, Y. C., and Tsai, M. C. 1996. Effects of paraquat on the substantia nigra of the Wistar rats: Neurochemical, histological, and behavioral studies. Toxicol. Appl. Pharmacol. 137:34-41.
40. Liou, H. H., Tsai, M. C., Chen, C. J., Jeng, J. S., Chang, Y. C., Chen, S. Y., and Chen, R. C. 1997. Environmental risk factors and Parkinson's disease: A case-control study in Taiwan. Neurology 48:1583-1588.
41. Lopes, U. G., Erhardt, P., Yao, R., and Cooper, G. M. 1997. p53-Dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272:12893-12896.
42. Maňáková, S., Puttonen, K., A., Raasmaja, A., and Mannisto, P. T. 2004. The roles of dopamine transporter and Bcl-2 protein in the protection of CV1-P cells from 6-OHDA-induced toxicity. Toxicol. Lett. 154:117-123.
43. Manning-Bog, A. B., McCormack, A. L., Li, J., Uversky, V. N., Fink, A. L., and Di Monte, D. A. 2002. The herbicide paraquat causes upregulation and aggregation of ?-synuclein in mice. J. Biol. Chem. 277:1641-1644.
44. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 287:1265-1269.
45. Masayo, S. N., Wakako, M., Yoji, K., Isobe, K., Masashi, T., Makoto, N., and Toshihiko, O. 2003. An inhibitor of mitochondrial complex I, rotenone inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J. Neurosci. Res. 74:589-597.
46. McCormack, A. L., Thiruchelvam, M., Manning-Bog, A. B., Thiffault, C., Langston, J. W., Cory-Slechta, D., and Di Monte, D. A. 2002. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 19:119-127.
47. McNaught, K. S., and Jenner, P. 2001. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:191-194.
48. McNaught, K. S., Olanow, C. W., Halliwell, B., Isacson, O., and Jenner, P. 2001. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:589-594.
49. McNaught, K. S., Belizaire, R., Jenner, P., Olanow, C. W., and Isacson, O. 2002. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326:155-158.
50. McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C. W. 2003. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179:38-46.
51. McNaught, K. S., Perl, D. P., Brownell, A. L., and Olanow, C. W. 2004. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56:149-162.
52. McNaught, K. S., Jackson, T., JnoBaptiste, R., Kapustin, A., and Olanow, C. W. 2006. Proteasomal dysfunction in sporadic Parkinson's disease. Neurology 66:S37-S49.
53. Moldeus, P., Hogberg, J., and Orrenius, S. 1978. Isolation and use of liver cells. Methods Enzymol. 52:60-71.
54. Onyon, L. J., and Volans, G. N. 1987. The epidemiology and prevention of paraquat poisoning. Hum. Toxicol. 6:19-26.
55. Pasquini, L. A., Marta, C. B., Adamo, A. M., Pasquini, J. M., and Soto, E. F. 2000. Relationship between the ubiquitin-dependent pathway and apoptosis in different cells of the central nervous system: Effect of thyroid hormones. Neurochem. Res. 25:627-635.
56. Presgraves, S. P., Ahmed, T., Borwege, S., and Joyce, J. N. 2004. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 5:579-598.
57. Roos-Mattjus, P., and Sistonen, L. 2004. The ubiquitin-proteasome pathway. Ann. Med. 36:285-295.
58. Ross, C. A., and Pickart, C. M. 2004. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 14:703-711.
59. Sanchez-Ramos, J. R., Hefti, F., and Weiner W. J. 1987. Paraquat and Parkinson's disease. Neurology 37:728.
60. Shamoto-Nagai, M., Maruyama, W., Kato, Y., Isobe, K., Tanaka, M., Naoi, M., and Osawa, T. 2003. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J. Neurosci. Res. 74:589-597.
61. Shamoto-Nagai, M., Maruyama, W., Akao, Y., Osawa, T., Tribl, F., Gerlach, M., Zucca, F. A., Zecca, L., Riederer, P., and Naoi, M. 2004. Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. J. Neural Transm. 111:1253-1265.
62. Shavali, S., Carlson, E. C., Swinscoe, J. C., and Ebadi, M. 2004. 1-Benzyl-1,2,3,4,-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases ?-synuclein expression and causes nuclear damage in human dopaminergic cells. J. Neurosci. Res. 76:563-572.
63. Sherer, T. B., Kim, J. H., Betarbet, R., and Greenamyre, J. T. 2003. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179:9-16.
64. Sherman, N. Y., and Goldberg, A. L. 2001. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 29:15-32.
65. Sun, F., Anantharam, V., Latchoumycandane, C., Kanthasamy, A., and Kanthasamy, A. G. 2005. Dieldrin induces ubiquitin-proteasome dysfunction in -synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death. J. Pharmcol. Exp. Ther. 315:69-79.
66. Tanaka, K., and Chiba, T. 1998. The proteasome: A protein-destroying machine. Genes Cells 3:499-510.
67. Tawara, T., Fukushima, T., Hojo, N., Isobe, A., Shiwaku, K., Setogawa, T., and Yamane Y. 1996. Effects of paraquat on mitochondrial electron transport system and catecholamine contents in rat brain. Arch. Toxicol. 70:585-589.
68. Theron, M., Guerrero, F., and Sebert, P., 2000. Improvement in the efficiency of oxidative phosphorylation in the freshwater eel acclimated to 10.1 MPa hydrostatic pressure. J. Exp. Biol. 203:3019-3023.
69. Vekrellis, K., Rideout, H. J., and Stefanis, L. 2004. Neurobiology of alpha-synuclein. Mol. Neurobiol. 30:1-21.
70. Vigouroux, S., Briand, M., and Briand, Y. 2004. Linkage between the proteasome pathway and neurodegenerative diseases and aging. Mol. Neurobiol. 30:201-221.
71. Yang, W., and Tiffany-Castiglioni, E. 2005. The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SHSY5Y cells: Relevance to the dopaminergic pathogenesis. J. Toxicol. Environ. Health A 68:1939-1961.
72. Yoshimoto, Y., Nakaso, K., and Nakashima, K. 2005. L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett. 579:1197-1202.
73. Zhang, J., Fitsanakis, V. A., Gu, G., Jing, D., Ao, M., Amarnath, V., and Montine, T. J. 2003. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: A link through mitochondrial dysfunction. J. Neurochem. 84:336-346.
74. Zheng, J., and Ramirez, V. D. 2000. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol. 130:1115-1123.
75. Zhou, Y., Shie, F. S., Piccardo, P., Montine, T. J., and Zhang, J. 2004. Proteasomal inhibition induced by manganese ethylene-bis-dithiocarbamate: Relevance to Parkinson's disease. Neuroscience 128:281-291.